| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.091 | 0.04 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.093 | 0.05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.092 | 0.05 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.09 | 0.05 |